Ulrike Fuhrmann – författare & böcker

Harald Schöffl, Horst Spielmann, Helmut A. Tritthart, Klaus Cußler, Ulrike Fuhrmann, Antoine F. Goetschl, Franz P. Gruber, Christoph Heusser, Helga Möller, Hansjörg Ronneberger, Angelo Vedani - Forschung ohne Tierversuche 1995, Häftad

Forschung ohne Tierversuche 1995

AvHarald Schöffl,Horst Spielmannm. fl.

Häftad, Tyska, 1995

841 kr

Skickas inom 10-15 vardagar

New Approaches to Drug Discovery

AvUlrich Nielsch,Ulrike Fuhrmannm. fl.

Inbunden, Engelska, 2016

2 173 kr

Skickas inom 10-15 vardagar

This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.

New Approaches to Drug Discovery

AvStefan Jaroch,Ulrike Fuhrmannm. fl.

E-bok

PDF, Engelska, 2016

2 822 kr

Läs direkt efter köp

This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.

Del 232 - Handbook of Experimental Pharmacology

New Approaches to Drug Discovery

AvUlrich Nielsch,Ulrike Fuhrmannm. fl.

Häftad, Engelska, 2018

2 238 kr

Skickas inom 10-15 vardagar

This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.

Molecular Basis of Sex Hormone Receptor Function

New Targets for Intervention

AvKarsten Parczyk,Ulrike Fuhrmannm. fl.

E-bok

PDF, Engelska, 2013

708 kr

Läs direkt efter köp

How sex hormone receptors and all the other members of the nuclear receptor superfamily do such a remarkable job has fascinated scientists for decades. A series of discoveries in the past few years has dramatically enlightened our understanding of the molecular mechanisms that govern nuclear receptor action. The elucidation of the 3D structures of several nuclear receptor ligand binding domains in the presence of agonists or antagonists has provided an allosteric concept of ligand action, and the discovery of a plethora of ligand-dependent protein interactions has linked this transconformation with the ability of nuclear receptors to act as transcriptional activators and repressors and the enzymatic modification of chromatin and factors of the basal transcriptional machinery.

Del 24 - Ernst Schering Foundation Symposium Proceedings

Molecular Basis of Sex Hormone Receptor Function

New Targets for Intervention

AvHinrich Gronemeyer,Ulrike Fuhrmannm. fl.

Häftad, Engelska, 2013

565 kr

Skickas inom 10-15 vardagar

How sex hormone receptors and all the other members of the nuclear receptor superfamily do such a remarkable job has fascinated scientists for decades. A series of discoveries in the past few years has dramatically enlightened our understanding of the molecular mechanisms that govern nuclear receptor action. The elucidation of the 3D structures of several nuclear receptor ligand binding domains in the presence of agonists or antagonists has provided an allosteric concept of ligand action, and the discovery of a plethora of ligand-dependent protein interactions has linked this transconformation with the ability of nuclear receptors to act as transcriptional activators and repressors and the enzymatic modification of chromatin and factors of the basal transcriptional machinery.